Volume 13 Issue 3
May  2022
Turn off MathJax
Article Contents
Zhao Wenyu, Zhu Youhua. Immunosuppressive management in pediatric kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 283-287. doi: 10.3969/j.issn.1674-7445.2022.03.001
Citation: Zhao Wenyu, Zhu Youhua. Immunosuppressive management in pediatric kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 283-287. doi: 10.3969/j.issn.1674-7445.2022.03.001

Immunosuppressive management in pediatric kidney transplant recipients

doi: 10.3969/j.issn.1674-7445.2022.03.001
More Information
  • Corresponding author: Zhu Youhua, Email: zhuyouhua@126.com
  • Received Date: 2022-01-16
    Available Online: 2022-04-29
  • Publish Date: 2022-05-15
  • In recent years, clinical efficacy of pediatric kidney transplantation has been gradually enhanced with persistent progress of organ allocation policy, surgical technologies and perioperative management, etc. However, immunosuppressive management still plays a significant role in the long-term prognosis of pediatric kidney transplant recipients. Due to the disparity from adults in physiology, psychology, immune system and drug metabolism, immunosuppressive management in children should be delivered in a specific manner. Therefore, it is necessary to select appropriate immunosuppresants and formulate individualized immunosuppressive regimens according to the characteristics of pediatric kidney transplant recipients in clinical practice. In this article, the characteristics of immunosuppressive therapy, selection of immunosuppresants, glucocorticoid withdrawal, immune monitoring and medication compliance management of pediatric kidney transplant recipients were investigated, aiming to provide reference for optimizing immunosuppressive management and improving clinical prognosis of pediatric kidney transplant recipients.

     

  • loading
  • [1]
    VERGHESE PS. Pediatric kidney transplantation: a historical review[J]. Pediatr Res, 2017, 81(1/2): 259-264. DOI: 10.1038/pr.2016.207.
    [2]
    FERRARESSO M, TUROLO S, BELINGHERI M, et al. Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment[J]. Pharmacogenomics, 2015, 16(5): 483-491. DOI: 10.2217/pgs.15.18.
    [3]
    ZONG YP, WANG ZJ, ZHOU WL, et al. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and Meta-analysis of observational studies[J]. World J Pediatr, 2017, 13(5): 421-426. DOI: 10.1007/s12519-017-0035-4.
    [4]
    HART A, SMITH JM, SKEANS MA, et al. OPTN/SRTR 2018 annual data report: kidney[J]. Am J Transplant, 2020, 20(Suppl s1): 20-130. DOI: 10.1111/ajt.15672.
    [5]
    ASHOOR IF, MARTZ K, GALBIATI S, et al. Reassessing rabbit antithymocyte globulin induction in kidney transplantation (RETHINK): an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry[J]. Transplant Direct, 2020, 6(9): e598. DOI: 10.1097/TXD.0000000000001042.
    [6]
    PULIYANDA DP, PIZZO H, RODIG N, et al. Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation[J]. Pediatr Transplant, 2020, 24(3): e13685. DOI: 10.1111/petr.13685.
    [7]
    SHANG W, FENG G, GAO S, et al. Reduced ATG-F dosage for induction in pediatric renal transplantation: a single-center experience[J]. Pediatr Transplant, 2014, 18(3): 240-245. DOI: 10.1111/petr.12224.
    [8]
    ASHOOR IF, BEYL RA, GUPTA C, et al. Low-dose antithymocyte globulin has no disadvantages to standard higher dose in pediatric kidney transplant recipients: report from the pediatric nephrology research consortium[J]. Kidney Int Rep, 2021, 6(4): 995-1002. DOI: 10.1016/j.ekir.2021.01.007.
    [9]
    KAABAK MM, BABENKO NN, SHAPIRO R, et al. Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction[J]. Pediatr Transplant, 2017, 21(5): e12941. DOI: 10.1111/petr.12941.
    [10]
    MINCHAM CM, WONG G, TEIXEIRA-PINTO A, et al. Induction therapy, rejection, and graft outcomes in pediatric and adolescent kidney transplant recipients[J]. Transplantation, 2017, 101(9): 2146-2151. DOI: 10.1097/TP.0000000000001577.
    [11]
    ANDREWS LM, HESSELINK DA, VAN GELDER T, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation[J]. Clin Pharmacokinet, 2018, 57(4): 475-489. DOI: 10.1007/s40262-017-0567-8.
    [12]
    MALAKASIOTI G, BOOTH C, MARKS SD. Converting immunosuppression from an oral suspension to a granule formulation of tacrolimus in pediatric renal transplant recipients[J]. Pediatr Transplant, 2018, 22(5): e13214. DOI: 10.1111/petr.13214.
    [13]
    VONDRAK K, PARISI F, DHAWAN A, et al. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus[J]. Clin Transplant, 2019, 33(10): e13698. DOI: 10.1111/ctr.13698.
    [14]
    FUKUDA T, GOEBEL J, COX S, et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients[J]. Ther Drug Monit, 2012, 34(6): 671-679. DOI: 10.1097/FTD.0b013e3182708f84.
    [15]
    AOKI Y, HAMASAKI Y, SATOH H, et al. Long-term outcomes of pediatric kidney transplantation: a single-center experience over the past 34 years in Japan[J]. Int J Urol, 2020, 27(2): 172-178. DOI: 10.1111/iju.14160.
    [16]
    PAPE L, AHLENSTIEL T. mTOR inhibitors in pediatric kidney transplantation[J]. Pediatr Nephrol, 2014, 29(7): 1119-1129. DOI: 10.1007/s00467-013-2505-9.
    [17]
    DUNMIRE SK, VERGHESE PS, BALFOUR HH JR. Primary Epstein-Barr virus infection[J]. J Clin Virol, 2018, 102: 84-92. DOI: 10.1016/j.jcv.2018.03.001.
    [18]
    WARD LM. Glucocorticoid-induced osteoporosis: why kids are different[J]. Front Endocrinol (Lausanne), 2020, 11: 576. DOI: 10.3389/fendo.2020.00576.
    [19]
    TÖNSHOFF B. Immunosuppressive therapy post-transplantation in children: what the clinician needs to know[J]. Expert Rev Clin Immunol, 2020, 16(2): 139-154. DOI: 10.1080/1744666X.2020.1714437.
    [20]
    BALANI SS, JENSEN CJ, KOURI AM, et al. Induction and maintenance immunosuppression in pediatric kidney transplantation-advances and controversies[J]. Pediatr Transplant, 2021, 25(7): e14077. DOI: 10.1111/petr.14077.
    [21]
    KUKLA A, CHEN E, SPONG R, et al. Recurrent glomerulonephritis under rapid discontinuation of steroids[J]. Transplantation, 2011, 91(12): 1386-1391. DOI: 10.1097/TP.0b013e31821bf157.
    [22]
    TÖNSHOFF B. Immunosuppressants in organ transplantation[J]. Handb Exp Pharmacol, 2020, 261: 441-469. DOI: 10.1007/164_2019_331.
    [23]
    LIVERMAN R, CHANDRAN MM, CROWTHER B. Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient[J]. Pharmacotherapy, 2021, 41(1): 77-102. DOI: 10.1002/phar.2483.
    [24]
    RESZTAK M, SOBIAK J, CZYRSKI A. Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies[J]. Pharmaceutics, 2021, 13(12): 1991. DOI: 10.3390/pharmaceutics13121991.
    [25]
    AHLENSTIEL-GRUNOW T, PAPE L. Novel ways to monitor immunosuppression in pediatric kidney transplant recipients-underlying concepts and emerging data[J]. Mol Cell Pediatr, 2021, 8(1): 8. DOI: 10.1186/s40348-021-00118-8.
    [26]
    HOEGY D, BLEYZAC N, ROBINSON P, et al. Medication adherence in pediatric transplantation and assessment methods: a systematic review[J]. Patient Prefer Adherence, 2019, 13: 705-719. DOI: 10.2147/PPA.S200209.
    [27]
    MEHTA P, STEINBERG EA, KELLY SL, et al. Medication adherence among adolescent solid-organ transplant recipients: a survey of healthcare providers[J]. Pediatr Transplant, 2017, 21(7): e13018. DOI: 10.1111/petr.13018.
    [28]
    CHISHOLM-BURNS MA, SPIVEY CA, REHFELD R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients[J]. Am J Transplant, 2009, 9(11): 2497-2504. DOI: 10.1111/j.1600-6143.2009.02793.x.
    [29]
    BOUCQUEMONT J, PAI ALH, DHARNIDHARKA VR, et al. Gender differences in medication adherence among adolescent and young adult kidney transplant recipients[J]. Transplantation, 2019, 103(4): 798-806. DOI: 10.1097/TP.0000000000002359.
    [30]
    NGUYEN C, DEW MA, IRIZARRY T, et al. Promoting medication adherence from the perspective of adolescent and young adult kidney transplant recipients, parents, and health care professionals: a TAKE-IT TOO study[J]. Pediatr Transplant, 2020, 24(5): e13709. DOI: 10.1111/petr.13709.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Article Metrics

    Article views (1164) PDF downloads(160) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return